Human IFN-γ ELISpot Kit (with CMV peptide pool)

Sample

Cells

Species Reactivity

Human

Detection Method

ELISpot

Intended Use

These assays can help identify individuals at higher risk of CMV disease by assessing their cellular immune response, thereby guiding antiviral prophylaxis and treatment strategies. Research has demonstrated that robust CMV-specific T cell responses correlate with lower rates of CMV disease post-transplantation, underscoring the importance of immune monitoring in managing CMV infections.

Contents of Kit

1. Peptide Pools​: Human CMV (37 peptides from pp65, IE1 and UL123 proteins)
2. Plates​: ELISpot plate precoated with IFN-γ capture antibody
3. Detection mAb​​: Biotinylated recombinant IFN-γ antibody
4. Enzyme conjugate​: Streptavidin-ALP (Alkaline Phosphatase)
5. Substrate: BCIP/NBT Ready-to-use solution
6. Blocking agent: Bovine Serum Albumin (BSA)

Storage

Store plates and reagents between 2 and 8°C. Peptide pool vial must be stored at -20 °C or below.

General Description

Human Cytomegalovirus (CMV) is a prevalent herpesvirus that infects most people worldwide. While CMV infection is often asymptomatic in healthy individuals, it poses significant health risks to immunocompromised patients, such as those undergoing organ transplantation, and to infants born to infected mothers. CMV infection is a significant cause of morbidity and mortality in these populations, leading to complications like pneumonia, retinitis, gastrointestinal disease, and encephalitis.

Assessment of CMV-specific cellular immunity is vital for controlling viral replication and preventing disease, particularly for recipients of donor transplants. ELISpot assays can be utilized to measure CMV-specific T cell responses by detecting cytokine production in response to viral peptides derived from CMV antigen.